Joyo starts its first pivotal trial
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
Roche pushes a novel myeloma target
The company will be the first to take a FcRH5-targeting project into phase 3.
Roche sets up a breast cancer déjà vu
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
What now for NK-cell engagers?
Big pharma interest remains, but the mood is fast turning gloomy.
In triple-negative pumitamig concedes PD-L1-high disease
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Lilly moves to overtake Relay
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
Daiichi makes its sting move
The recently unveiled conjugate DS3610a is to start phase 1.
Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Chia Tai keeps the TGF-β faith
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
Kura harks back to its roots
After menin, the company tries again with farnesyl transferase.
